first
influenza
pandem
centuri
emerg
mexico
march
caus
novel
influenza
viru
gener
cours
pandem
moder
publichealth
perspect
howev
particular
proport
human
popul
includ
immunocompromis
patient
children
pregnant
women
risk
develop
sever
diseas
hemagglutinin
ha
neuraminidas
na
repres
two
major
surfac
glycoprotein
influenza
viru
ha
determin
hostreceptor
tropism
constitut
key
immunogen
site
human
immun
respons
sinc
begin
pandem
rapidli
evolv
seven
differ
cladesgroup
character
distinct
molecular
marker
ha
gene
report
mutat
receptorbind
domain
ha
gene
link
sever
case
note
anoth
mutat
involv
residu
also
observ
could
associ
sever
case
understand
molecular
evolut
influenza
viru
therefor
crucial
identifi
mutat
might
associ
virul
phenotyp
second
surfac
glycoprotein
na
facilit
releas
newli
synthes
virion
infect
cell
neuraminidas
block
antivir
drug
oseltamivir
zanamivir
act
interf
releas
progeni
viru
therebi
prevent
new
round
infect
singl
point
mutat
posit
neuraminidas
glycoprotein
result
histidinetotyrosin
shift
confer
resist
oseltamivir
aim
studi
investig
molecular
evolut
influenza
season
southern
germani
sequenc
analysi
ha
gene
mild
moder
sever
influenza
case
particular
attent
paid
immunocompromis
patient
moreov
occurr
resist
oseltamivir
drug
current
recommend
prophylaxi
highrisk
group
determin
respiratori
specimen
obtain
paediatr
adult
patient
hospit
freiburg
univers
medic
centr
well
outpati
influenzalik
ill
includ
fever
cough
andor
sore
throat
judg
treat
physician
respiratori
specimen
compris
nasopharyng
aspir
npa
tonsillopharyng
flock
swab
collect
ml
viral
transport
medium
copan
brescia
itali
bronchoalveolar
lavag
fluid
bal
analys
depart
virolog
test
patient
sampl
approv
institut
review
board
freiburg
univers
brief
nucleic
acid
extract
use
qiaamp
minelut
viru
spin
kit
qiagen
hilden
germani
qiacub
robot
qiagen
accord
manufactur
instruct
broadli
reactiv
multiplex
pcr
approach
chosen
detect
influenza
virus
b
well
relev
respiratori
virus
sampl
analys
use
ftd
respiratori
pathogen
version
fasttrack
diagnost
junglinst
luxemburg
recommend
assay
util
nucleas
technolog
taqman
employ
multiplex
onestep
realtim
rtpcr
approach
tube
realtim
rtpcr
influenza
viru
influenza
viru
b
rhinoviru
combin
tube
contain
reagent
parainfluenza
virus
brome
mosaic
viru
bmv
pcr
inhibit
control
tube
coronaviru
coronaviru
coronaviru
coronaviru
tube
respiratori
syncyti
viru
ab
adenoviru
parechoviru
enteroviru
tube
parainfluenza
viru
human
metapneumoviru
ab
human
bocaviru
mycoplasma
pneumonia
bmv
inhibit
control
ad
patient
sampl
nucleic
acid
extract
agpathid
onestep
rtpcrkit
invitrogen
karlsruh
germani
use
rtpcr
abi
realtim
machin
appli
biosystem
wiesbaden
germani
cycl
condit
follow
min
min
follow
amplif
cycl
denatur
combin
annealingextens
detect
oseltamivirresistanceassoci
mutat
commerci
avail
assay
tibmolbiol
berlin
germani
use
accord
manufactur
instruct
ha
gene
amplifi
directli
clinic
sampl
use
superscript
tmiii
onestep
rtpcr
system
invitrogen
karlsruh
germani
brief
reaction
volum
contain
reaction
buffer
mm
primer
enzym
mix
purifi
nucleic
acid
primer
sequenc
follow
ccg
caa
atg
cag
aca
cat
ta
ccc
att
aga
gca
cat
cca
gaa
cycl
condit
veriti
thermal
cycler
appli
biosystem
weiterstadt
germani
min
min
follow
amplif
cycl
pcr
product
purifi
use
qiaquick
pcr
purif
kit
qiagen
recommend
purifi
pcr
product
sequenc
directli
use
primer
ccgcaaatgcagacacatta
cagacacccaagggtgctat
sequenc
align
use
bioedit
mega
nucleotid
sequenc
align
done
use
clustalw
method
mega
phylogenet
tree
construct
use
maximumparsimoni
method
ncbi
genbank
access
number
sequenc
determin
amino
acid
number
start
dtlc
signal
peptid
potenti
nlink
glycosyl
site
predict
use
free
softwar
netnglyc
data
analyz
use
spss
softwar
version
spss
chicago
usa
data
compar
fisher
exact
test
pvalu
deem
signific
level
order
detect
molecular
chang
ha
gene
influenza
viru
ha
sequenc
repres
individu
patient
analys
shown
tabl
patient
immunocompromis
immunosuppress
suffer
differ
underli
diseas
viru
isol
mdck
cell
obtain
respiratori
sampl
data
shown
median
age
patient
year
confid
interv
ci
year
base
clinic
criteria
regard
mild
median
age
year
rang
year
moder
median
age
year
rang
year
sever
case
median
age
year
rang
year
accord
zarychanski
et
al
sever
case
hospit
patient
known
risk
sever
diseas
patient
immunocompromis
one
obes
immunocompet
patient
immunocompromis
patient
develop
sever
diseas
fisher
exact
test
sampl
correspond
patient
coinfect
anoth
respiratori
viru
detect
coronaviru
andor
detect
patient
rsv
human
bocaviru
codetect
npa
one
rsv
alon
detect
pharyng
swab
anoth
patient
clinic
patient
rsv
bocaviru
coinfect
present
mild
diseas
remain
patient
display
moder
sever
symptom
none
patient
show
coinfect
mycoplasma
pneumonia
assess
multiplex
pcr
prolong
shed
e
week
influenza
viru
respiratori
tract
observ
patient
sever
moder
mild
diseas
total
patient
immunocompromis
patient
immunocompromis
receiv
oseltamivir
therapi
ha
sequenc
close
relat
refer
strain
differ
german
sequenc
rang
amino
acid
tabl
virus
analys
display
amino
acid
chang
region
well
e
k
region
phylogenet
analysi
show
simultan
cocircul
influenza
viru
group
southern
germani
figur
genet
group
name
accord
ecdc
technic
document
augustseptemb
detail
sequenc
belong
genet
group
character
doubl
mutat
moreov
show
addit
mutat
influenza
one
mutat
note
particular
strain
isol
influenzavaccin
individu
ten
sequenc
belong
genet
group
character
mutat
group
three
also
mutat
observ
piralla
et
al
two
subclust
seen
within
group
group
character
amino
acid
mutat
includ
four
sequenc
obtain
patient
final
sequenc
cluster
within
group
character
mutat
doubl
mutat
characterist
group
group
observ
sever
moder
mild
case
scatter
throughout
phylogenet
tree
observ
amino
acid
substitut
involv
major
antigen
site
ha
molecul
tabl
five
potenti
nglycosyl
site
typic
correspond
residu
also
detect
german
sequenc
howev
two
patient
two
addit
glycosyl
site
detect
residu
lysin
asparagin
one
case
serin
asparagin
case
shown
tabl
correspond
sequenc
obtain
upper
lower
respiratori
tract
patient
interestingli
mutat
repres
addit
potenti
nglycosyl
site
present
bal
sampl
moreov
cycl
threshold
ct
valu
realtim
rtpcr
throat
swab
compar
bal
sampl
suggest
higher
concentr
viru
lower
upper
respiratori
tract
similarli
anoth
sever
case
ct
valu
bal
sampl
obtain
day
onset
diseas
lower
ct
nasopharyng
swab
ct
also
case
two
addit
amino
acid
chang
genbank
access
number
detect
bal
sampl
treatment
oseltamivir
report
patient
immunocompromis
patient
obes
patient
oseltamivirresistanceassoci
mutat
detect
treat
patient
oneyearold
child
genet
disord
treat
day
oseltamivir
recov
fulli
influenza
despit
develop
oseltamivir
resist
prolong
shed
resist
viru
week
molecular
studi
abl
show
influenza
virus
circul
southern
germani
first
postpandem
season
differ
rel
littl
vaccin
strain
amino
acid
substitut
observ
involv
major
antigen
site
ha
molecul
five
classic
antigen
site
sa
sb
cb
describ
ha
season
influenza
viru
locat
globular
head
ha
recent
studi
also
describ
import
antigen
site
stem
region
ha
virus
analys
amino
acid
chang
region
region
report
other
publish
ecdc
report
releas
augustseptemb
cocircul
differ
genet
group
observ
group
character
mutat
domin
lineag
follow
group
group
group
although
number
mutat
report
circul
significantli
affect
viru
antigen
pathogen
demonstr
vitro
studi
clinic
mutat
n
associ
virul
phenotyp
howev
recent
studi
show
within
current
ha
framework
effect
mutat
receptor
bind
appear
less
dramat
compar
influenza
viru
ha
framework
sinc
bind
prefer
sialylglycan
still
maintain
also
mutat
doubl
mutat
associ
virul
phenotyp
doubl
mutat
associ
sever
breakthrough
infect
despit
influenza
vaccin
identifi
fatal
case
moreov
associ
decreas
antibodi
recognit
vaccin
individu
german
ha
sequenc
carri
doubl
mutat
origin
unvaccin
immunocompromis
individu
sever
ill
due
lack
serum
specimen
could
analyz
abil
antibodi
recogn
hemagglutinin
studi
howev
immun
escap
vaccin
strain
might
issu
concern
chang
observ
studi
associ
specif
amino
acid
chang
sever
ill
could
observ
howev
two
patient
differ
ha
sequenc
could
detect
virus
isol
either
upper
respiratori
tract
urt
lower
respiratori
tract
lrt
particular
two
addit
mutat
one
case
case
identifi
lrt
moreov
analysi
potenti
glycosyl
site
reveal
mutat
provid
addit
potenti
glycosyl
site
human
influenza
virus
carri
mutat
show
improv
growth
egg
appear
exhibit
enhanc
virul
mous
model
glycosyl
posit
essenti
improv
viru
protein
yield
egg
egg
adapt
human
influenza
virus
known
increas
affin
acid
sa
receptor
concomitantli
impair
abil
bind
although
clear
influenza
viru
tropism
depend
sever
viral
host
factor
ha
specif
presenc
mutat
exclus
viru
isol
lrt
might
indic
effici
bindingrepl
virus
carri
mutat
toin
cell
express
importantli
known
found
abund
lower
respiratori
tract
note
ct
valu
realtim
rtpcr
nasopharyng
swab
higher
bal
sampl
carri
mutat
ct
versu
ct
sinc
bal
sampl
usual
significantli
dilut
nasopharyng
swab
observ
differ
suggest
real
replic
advantag
strain
harbour
lrt
viru
histochemistri
studi
could
use
analyz
pattern
bind
mutant
human
respiratori
tissu
alreadi
suggest
moreov
analysi
growth
curv
two
isol
differ
cell
line
may
reveal
possibl
replic
advantag
least
cell
cultur
mani
patient
influenza
one
viral
agent
report
coinfect
frequenc
high
detect
coinfect
anoth
respiratori
viru
sampl
correspond
patient
frequent
coinfect
agent
coronavirus
sampl
follow
rsv
sampl
human
bocaviru
diseas
result
coinfect
influenza
viru
coronavirus
report
sever
although
number
influenza
viru
coronaviru
coinfect
low
patient
coinfect
coronavirus
show
moder
sever
diseas
wherea
coinfect
rsv
human
bocaviru
one
child
result
mild
diseas
final
oseltamivirresistanceassoci
mutat
detect
studi
popul
although
oseltamivir
wide
use
pandem
thereaft
case
resist
remain
scarc
date
howev
prolong
shed
high
level
resist
influenza
viru
individu
case
pose
threat
spread
popul
risk
final
gener
popul
resist
virus
retain
fit
concord
studi
result
underlin
import
monitor
influenza
viru
evolut
develop
resist
virus
note
lrt
might
harbour
virul
variant
urt
immun
escap
influenza
viru
subsequ
influenza
season
issu
concern
make
continu
surveil
essenti
